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Since end of 2019, the severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2) has spread from Wuhan, China 
to the rest of the world, leading to more than 160 million 
confirmed cases of coronavirus disease 2019 (COVID-19) 
with more than 3.3 million deaths worldwide [1]. COVID-
19 results in a spectrum of clinical manifestations ranging 
from asymptomatic to critical illness including acute res-
piratory distress syndrome (ARDS) and multiorgan failure, 
which are associated with high morbidity and mortality. Fac-
tors that increase risk for an adverse disease course include 
older age and the presence of comorbidities such as diabe-
tes, hypertension, chronic kidney disease, morbid obesity, 
coronary heart disease, and chronic lung disease [2]. Solid 
organ transplant (SOT) patients are considered to be at high 
risk for complications from COVID-19 because of the high 
prevalence of the comorbidities that have been established 
as risk factors for severe disease, as well as a higher risk 
of infection due to their immunosuppressed status [3, 4]. 
Current data on the clinical course of COVID-19 in immu-
nocompromised patients are limited.
Vaccination against COVID-19 may be an effective inter-
vention in fighting the pandemic. Several SARS-CoV-2 
vaccines have been approved for administration in various 
countries and are available to select populations based on 
local recommendations and regulations. Current efficacy 
data from randomized clinical trials in immunocompetent 
recipients are variable as noted in Table 1, but thus far con-
sistently demonstrate close to 100% protection against severe 
COVID-19-related intensive care hospitalization or death 
[5]. Observational “real-world” findings from Israel, includ-
ing 596,618 vaccinated persons matched to unvaccinated 
controls, demonstrated an 87% reduction in COVID-19-re-
lated hospitalization following administration of two doses 
of the Pfizer-BioNTech vaccine [6]. Safety and efficacy data 
for SARS-CoV-2 vaccines in transplant recipients are lim-
ited thus far, as transplant recipients were not included in the 
already published randomized vaccine trials [5]. However, 
guidelines regarding COVID-19 vaccination in patients with 
thoracic transplantation have been released by the Interna-
tional Society for Heart and Lung Transplantation (ISHLT) 
and the American Society for Transplantation (AST) in a 
combined statement [7], as well as by the European Society 
of Cardiology (ESC) [8], unequivocally recommending vac-
cination at least 1 month after transplant surgery.
In this issue of the Journal, Schramm and colleagues [9] 
report on a prospective cohort study of the immune response 
after administration of the BNT162b2 vaccine in 50 cardio-
thoracic (heart (n = 42), lung (n = 7) or heart–lung (n = 1)) 
transplant recipients from 5 German transplant centers 
10–36 months after transplantation, compared to 50 healthy 
staff members similarly immunized with the same messenger 
RNA (mRNA) vaccine. Antibody titers, functional inhibi-
tory capacity of neutralizing antibodies, and T-cell response 
(interferon-γ release) were measured via three separate tests. 
Forty-six (92%) of the transplant recipients did not show 
any humoral or T-cell response 21 days after completion 
 * Sebastian Ewen 
 sebastian.ewen@uks.eu
1 Klinik für Innere Medizin III, Kardiologie, Angiologie 
und Internistische Intensivmedizin, Universitätsklinikum 
des Saarlandes und Medizinische Fakultät der Universität 
des Saarlandes, Kirrberger Str. 100, 66421 Homburg, Saar, 
Deutschland
2 Klinik für Innere Medizin I, Onkologie, Hämatologie, 
Klinische Immunologie und Rheumatologie, 
Universitätsklinikum des Saarlandes und Medizinische 
Fakultät der Universität des Saarlandes, Homburg, Saar, 
Deutschland
3 I. Medizinische Klinik, Kardiologie, Pneumologie, 
Internistische Intensivmedizin, Endokrinologie, 
Universitätsklinikum Augsburg, Augsburg, Deutschland
1140 Clinical Research in Cardiology (2021) 110:1139–1141
1 3
of the second vaccine dose [9]. In contrast, humoral vac-
cination success (IgG antibodies and neutralizing antibod-
ies) in healthy controls was seen in 49 subjects (98%) after 
the first vaccine dose, and in 100% after the second vaccine 
dose [9]. Additionally, healthy controls developed a signifi-
cantly higher positive T-cell response (interferon-γ release) 
compared to transplant recipients (80% vs 16%) [9]. It is 
concluded that the BNT162b2 vaccine does not confer vac-
cination success against SARS-CoV-2 in the vast majority 
of cardiothoracic transplant recipients.
The presented data indicate that patients receiving immu-
nosuppression are less likely to respond to mRNA-based 
SARS-CoV-2 vaccination compared to immunocompetent 
participants included in SARS-CoV-2 vaccine trials [10]. 
Although data regarding the new vaccine technology using 
mRNA in transplant recipients are scarce, it is known that 
patients who underwent a transplant do not develop optimal 
immune responses following many vaccines (e.g., influ-
enza vaccination) [11]. The reasons for this are multifacto-
rial but may include (i) the time since transplantation, (ii) 
the amount and nature of immunosuppression and (iii) the 
occurrence of concomitant allograft rejection that interferes 
with the production of the requisite neutralizing antibod-
ies [12]. A study of COVID-19 vaccine responses among 
kidney transplant recipients indicated that all 25 members 
of the control group developed a positive humoral immune 
response to the viral spike proteins, compared with only 
37.5% out of 136 transplant recipients who had a positive 
serology test [13]. A prospective cohort study including 658 
SOT recipients (97 heart recipients and 71 patients who 
underwent lung transplantation) across the US showed that 
only a low proportion (15%) of transplant patients mounted a 
positive antibody response after the first vaccine dose, which 
increased to 54% of transplant recipients after dose 2 [12]. 
Although this study demonstrates an increase in antibody 
responses in transplant patients after the second vaccine 
dose compared with the first, data indicates, in line with the 
investigation presented herein, that a substantial proportion 
of transplant patients are likely to remain at risk for COVID-
19 despite being administered a full dose of an mRNA-
based vaccine. Currently, there are not enough comparative 
studies in transplant patients evaluating the differences in 
immune response to the various COVID-19 vaccine types 
already developed. Therefore, further studies are urgently 
needed to address interventions including different types 
of vaccination, additional booster doses, optimization of 
t-cell responses of current vaccines or immunosuppression 
modulation to improve vaccine responses in this high-risk 
population. Larger, multicenter studies also need to be per-
formed to disentangle the group of non-responders from the 
group who would benefit from traditional dosing. It remains 
unclear whether a lack of antibody response after COVID-19 
vaccination is associated with a higher risk of infection or a 
worse course of the disease after infection.
Although the exact impact of chronic immunosuppres-
sion on COVID-19 outcomes remains ambiguous as of 
today, its role seems to be highly relevant as host inflamma-
tory responses appear to constitute an important cause of 
associated organ injury [3]. As the manifestations of severe 
COVID-19, including ARDS and organ dysfunction, may 
be propagated by a proinflammatory state due to cytokine 
release syndrome, immunosuppressive therapy could poten-
tially mitigate some of these effects and thereby help prevent 
severe complications in SOT patients [3]. One multicenter 
study comparing ICU COVID-19-positive SOT recipients 
with matched controls found no difference in rates of ARDS 
or death between groups [3]. Although some smaller single-
center studies have shown excess mortality in patients who 
underwent a transplant, many were conducted in regions 
with overwhelmed hospital systems at the time of patient 
presentation [14]. In the case of vulnerable, immunocom-
promised patients with a severe disease course, passive 
immunization against COVID-19 using convalescent sera 
or engineered antibody cocktails might be an option, barring 
circulating resistant variants. However, in 228 randomized 
hospitalized patients with severe COVID-19 pneumonia, no 
Table 1  SARS-CoV-2 
vaccinations available globally, 
as of May 10, 2021 (Adapted 
from [5])
Manufacturer Type Vaccine efficacy reported in 
clinical trials (%)
Prevention of severe disease 
leading to death in clinical trials 
(%)
Pfizer/BioNTech mRNA 95 100
Moderna mRNA 94.5 100
Sputnik V Ad26/Ad5 91.4 100
AstraZeneca ChAdOx1 60–85 100
Johnson & Johnson Ad26 57–72 100
Cansino Ad5 66 100
Sinopharm Inactivated 79.6–86 100
Sinovac Inactivated 50.1 100
Novavax Protein 86–96 100
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significant differences in clinical status or mortality were 
detected after 30 days between patients treated with conva-
lescent plasma and those who received placebo [15].
COVID-19 will likely circulate for many years, if not 
indefinitely. Based on the presented findings, routinely test-
ing for antibody response (or even T-cell response) in trans-
plant recipients following COVID-19 vaccination should 
be strongly recommended to prevent false security in this 
high-risk group. All transplant recipients have to be coun-
seled to continue practicing protective measures including 
mask use, hand hygiene, and social distancing even if they 
are vaccinated. As with other very contagious viral patho-
gens such as measles, real protection of the immunocompro-
mised could only be possible by vaccinating relatives and 
all fellow human beings to achieve “herd immunity”. The 
ultimate question that remains is whether it should continue 
to be recommended that all patients be vaccinated against 
COVID-19 after heart or lung transplants—as of today, the 
answer is YES! But more effective, yet unclear strategies 
are urgently needed.
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